Anivive Lifesciences Receives FDA Approval for Oral Treatment of Canine Lymphoma
Anivive Lifesciences has received full FDA approval for its oral treatment, Laverdia (verdinexor tablets), the first at-home therapy for canine lymphoma. The drug was developed using Anivive's AI-enabled platform and is expected to offer a more accessible option in veterinary oncology.
Topics: ai drug development pharmaceuticals veterinary medicine